
---
title: '南京新百：将于近期启动Sipuleucel-T注射液Ⅲ期关键性注册临床试验'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=1133'
author: 证券时报网
comments: false
date: Thu, 28 Jul 2022 18:29:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=1133'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600682" style="color: #2f67d1;text-decoration: none;" code="600682" target="_blank">南京新百</a>(600682)7月28日晚间公告，控股子公司上海丹瑞将于近期启动Sipuleucel-T注射液Ⅲ期关键性注册临床试验。</p>

                  
</div>
            